July 22nd 2024
Participants with AF who used wearable devices reported higher anxiety levels and increased health care usage than nonusers, according to a new study.
ACC: Heart-Healthy Menus Can Vary With Equal Outcomes
March 26th 2007NEW ORLEANS -- In the first mouth-to-mouth comparison between the omega-3 heavy Mediterranean and the AHA's low-fat diets for secondary prevention, outcomes didn't seem to differ so long as MI patients stuck with dietary intervention.
ACC: Novel Anticoagulant May Sidestep Bleeding Risk
March 25th 2007NEW ORLEANS -- An investigational oral thrombin receptor antagonist led to a trend toward reduced fatal and non-fatal cardiac events, with a low bleeding risk, in a phase II trial of patients with percutaneous coronary interventions, mostly stenting.
Managing IPF: Taking a hard look at today's choices
March 1st 2007**IPF is the most common form of idiopathic interstitial lung disease. The recent development of histopathological and clinical criteria that accurately define IPF has resulted in expansion of our scientific knowledge, development of novel therapies, and initiation of high-quality clinical trials.
Young Child With Hematuria and Dysuria
March 1st 2007A 3-year-old girl is brought to the office because of a1-week history of hematuria and dysuria. Her motherhad noticed bright red blood in the child’s urine anddiaper. The child did not have dysuria initially but latercomplained of a burning sensation.
'Prehypertension' Called Heart Risk in Postmenopausal Women
February 19th 2007WASHINGTON -- An observational study of 60,000 postmenopausal women found that about 40% have prehypertension, and that level of blood pressure was associated with a 58% higher risk of cardiovascular death than for normotensive women.
What caused these findings in a patient with atrial fibrillation?
February 1st 2007A 69-year-old man with a history of atrial fibrillation, pulmonary embolism, asthma, and obstructive sleep apnea presented to the emergency department for evaluation of dyspnea and light-headedness. He had been treated for paroxysmal atrial fibrillation over the past 5 years; fairly good control had been achieved with metoprolol and amiodarone. However, over the past several months, he had been experiencing intermittent episodes of atrial fibrillation.
Discordant ECG Findings in a Man With Chest Pain
February 1st 2007An 80-year-old man presents to the emergency department (ED) with intermittent dyspnea and chest pain. He has hypertension and osteoarthritis but no known cardiac disease. Vital signs are normal. No jugular venous distention is noted. The lungs are clear with equal breath sounds, and the heart rate is regular, without murmurs, gallops, or rubs. The chest wall is not tender. No edema or asymmetry is evident in the extremities.
Heart Failure: Patient Selection and Treatment
February 1st 2007ABSTRACT: Angiotensin-converting enzyme (ACE) inhibitor therapy is recommended for all patients with heart failure (HF) and a reduced ejection fraction. It is generally initiated in the hospital at low doses as inotropic therapy is tapered. Angiotensin II receptor blockers may be a suitable alternative for patients who cannot tolerate ACE inhibitors. For patients who cannot tolerate either class of drug, a combination of hydralazine and a nitrate is recommended. ß-Blockers are first-line therapy for patients with current or previous symptoms of HF and reduced left ventricular function, as well as all patients hospitalized for HF. An aldosterone antagonist may be added to the regimen of patients with moderately severe to severe symptoms and reduced ejection fraction whose renal function and potassium concentration can be monitored.
Managing acute severe asthma, part 1: What therapies to try, and when
February 1st 2007The initial assessment of acute severe asthma includes confirmation of the diagnosis and rapid assessment of mental status and degree of respiratory distress. The severity of airflow obstruction is best determined by forced expiratory volume in 1 second or peak expiratory flow rate. While inhaled ß2-agonists are the initial therapy, the combination of ipratropium and a ß2-agonist can enhance results in some patients. There also is evidence that inhaled corticosteroids can lead to a more rapid improvement in pulmonary function. (J Respir Dis. 2007;28(2):57-64)